AbbVie relies on a high-margin biopharmaceutical portfolio and significant free cash flow to drive shareholder value. Abbott Laboratories leverages a highly diversified business model spanning medical devices, diagnostics, and nutritional products.
Investors interested in stocks from the Medical - Products sector have probably already heard of Envista (NVST) and Abbott (ABT). But which of these two stocks offers value investors a better bang for their buck right now?
Abbott broadens Diagnostics growth with Exact Sciences, as Cancer Diagnostics gains and resilient routine testing offset respiratory weakness.
Abbott Laboratories (NYSE:ABT | ABT Price Prediction) currently trades at $105.70, while the Street's consensus price target sits at $118.42, implying roughly 12% of upside.
Abbott Laboratories maintains a diversified business model spanning diagnostics, medical devices, and nutrition products. Eli Lilly is experiencing rapid growth driven by its dominant presence in the cardiometabolic treatment market.
Abbott Laboratories leverages a diversified portfolio across medical devices and diagnostics, bolstered by its recent acquisition of Exact Sciences. Johnson & Johnson maintains superior net margins and massive scale within its pharmaceutical and medical technology divisions.
NOBL is outperforming SPY YTD in 2026, returning 12.9% versus SPY's 7.88%, with 45 Aristocrats ahead of SPY. Dividend growth among Aristocrats in 2026 averages 4.10%, with recent increases from ALB, FAST, PPG, SJM, and SWK. 25 Dividend Aristocrats appear undervalued and offer estimated long-term annualized returns of at least 10% using dividend yield theory.
Novartis is expertly handling massive patent cliffs, which speaks volumes about how resilient its business is. Abbott Laboratories has attractive long-term opportunities within its core medical device market.
Abbott Laboratories, Taiwan Semiconductor, and Johnson & Johnson have all delivered strong earnings releases in the Q2 cycle, with each breaking records while also lifting their outlooks.
ABT is expanding across diabetes care, oncology diagnostics and heart devices, with new launches and acquisitions creating multiple growth paths to watch.